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Abstract
Background: One challenge in caring for cancer patients with incurable disease is the adequate identification of
those in need for specialized palliative care (SPC). The study’s aim was to validate an easy to use phenomenological
screening tool.
Methods: The German tool is based on the National Comprehensive Cancer Network (NCCN) Palliative Care
guidelines and contains ten items in five domains that focus e.g. on diagnosis, functional status, complications,
comorbidities, and palliative care relevant problems such as symptom management, distress, and support of family
and team members. Sum score ranges from 0 to 14 (no need to great need). Assessment to identify SPC needs was
done in university hospital wards between 1 and 08/2017 by health care professionals on admission of the patient
if the disease was incurable and expected prognosis < 12 months. The Integrated Palliative Outcome Scale (IPOS,
staff version), an outcome assessment instrument for palliative care that consists of ten items, served as external
criterion; in sub samples inter-rater/test-retest were performed.
Results: Data from 208 patients with incurable disease and life expectancy < 12 months (54.8% female; average age
63.5 years, range 21–96) were assessed using the tool. The tool has good convergent validity; the correlation
between the sum scores of IPOS and our tool showed a significant and substantial effect. The sum score was
independent of the patient’s age, gender and primary diagnosis. Patients who already were in contact with SPC
had significantly higher screening scores than patients without. With a cut point of ≥ 5, 80.8% of the screened
patients were in need for SPC. Cronbach’s alpha was α = .600. Rater agreement (inter-rater, test-retest) varied
between single items. Correlation coefficients showed significant substantial effects.
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Conclusions: This is the first validation of a screening procedure in German language identifying SPC needs of
adult patients with advanced cancer and the first using filter questions as a pre-screening. Proxy assessment of SPC
needs by physicians in cancer care settings is feasible and the suggested tool presents a valid instrument to trigger
a PC consultation.
Trial registration: The study was not registered.
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Background
Comprehensive oncological treatment achieved ground-
breaking advancement over the last decades and in many
patients diagnosed with cancer survival has increased
significantly. However, in a substantial number of
patients cancer progresses and a need for specialized
palliative care may evolve at some point during the
disease trajectory. The Palliative Care (PC) approach of-
fers – on a generalized or specialized level - continuity
of care including symptom management as well as psy-
chosocial and spiritual support for all patients with life
limiting diseases [1]. Patients may be treated in parallel
with oncological experts or - in case of more complex
needs - exclusively by multi-professional specialized
palliative care (SPC) professionals.
Here, one of the major challenges is the adequate identi-
fication of patients in need for SPC. Timely SPC integra-
tion has shown to improve quality of care, reduce costs,
and may even increase patients’ survival time [2–4]. The
causes for late referrals are multifaceted. Still oncologists
and their patients may have an inadequate awareness of
palliative care. Difficulties in prognostication may also
hamper timely access. A recent follow-up study on
patients cared for by a German inpatient SPC service at a
tertiary center showed that less than 5% were seen for the
first time more than 6months before death and median
survival from this first contact was 24 days [5]. To foster a
fair and appropriate access for patients’ systematic screen-
ing on needs for SPC may be beneficial. Hence for
Germany there is a scarcity of validated screening tools
and that is one more cause that patients are often identi-
fied too late in the disease trajectory.
In cancer, the actual stage of the disease was proposed
as a threshold to integrate SPC [6]. However, not every
patient with advanced disease requires SPC and at the
contrary, patients at an earlier stage may already have
needs for SPC. For a mixed population with cancer and
non-cancer patients general indicators for deterioration
in health status and approaching death were developed
and evaluated [7]. These indicators may help to deter-
mine the need for SPC and may prompt clinicians to
initiate needs assessment and advance care planning.
However, it may fail in identification of the need for SPC
and in particular in daily routine.
The evidence on screening for the detection of the
need to integrate SPC is scarce. For cancer patients,
three different possible determinants are discussed:
First, the need for SPC could be defined by the actual
disease/stage of the disease as proposed by Gaertner et
al. [6], but this disease specific determination has not yet
been further evaluated.
Second, the need for SPC could be defined by profes-
sionals. For that purpose, Glare/Chow [8] developed a
phenomenological tool for professionals that classified
34% of all cancer patients in an outpatient clinic in need
for SPC. Trout et al. [9] developed a rather medically
oriented proxy tool combining primary disease, number
of co-morbidities, the level of performance status
defined by the Eastern Cooperative Oncology Group
(ECOG) [10], and intensity of a set of core symptoms
(pain, depression, fatigue, nausea, cognitive impairment,
and dyspnoea). According to a - from our perspective
artificially set - threshold, 13% of inpatients with cancer
diagnosis were in need for a SPC consultation [9].
Thirdly, patients’ self-assessment could be used to
identify the need for SPC. Morita et al. used patients’
self-assessment including the distress thermometer and
identified 23% of cancer patients in need for SPC [11].
For a mixed population with cancer and non-cancer
diagnosis, Highet et al. proposed prognosis as well as
disease and non-disease specific determinants (e.g.
weight loss, unplanned hospital admissions) to identify
deterioration in health status and approaching death
resulting in a need for PC in general [7]. In case of ad-
vanced organ failure they identified 41% of renal patients
and 83% of patients treated by the liver unit to be in a
deteriorated health status and approaching death [7].
All-in-all the level of evidence is low and the results of
the existing studies are rather heterogeneous.
None of the instruments above are validated and rou-
tinely used for screening for SPC in Germany.
Study aim
The aim of this project is to develop and validate an
easy to use, routine and patient-centered strategy for
identification of cancer patients in need for SPC
taking disease and prognosis as well as the patients’,
families’ and their carers’ needs into account. A
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practical and feasible screening instrument should be
usable as proxy assessment with little workload bur-
den for the clinicians as not all patients are capable
of self-assessment. The manuscript presented here
aims to improve clinical practice to trigger a PC con-
sultation and foster the international discussion on
screening for SPC.
Methods
Development of the screening tool
A scoping review of the literature on screening tools for
SPC needs was conducted. The mode of development,
mode of assessment, target groups, settings, identifica-
tion criteria, and threshold/trigger points were collected.
Based on these data, a patient-centered screening tool
following the National Comprehensive Cancer Network
(NCCN) criteria as described by Glare/Chow [8] with an
implementation strategy was developed and discussed in
a multidisciplinary (physicians, psychologist, nurse) and
interdisciplinary (respiratory medicine, haematology/on-
cology, gynaecology and palliative medicine) expert
group within our comprehensive cancer center. We de-
cided on those disciplines following the competencies
needed to successfully conduct the study: for the
psychometric aspects we choose a psychologist, for the
patient care and organizational aspects on conducting
the screening we choose physicians and a study nurse.
The four disciplines are part of the comprehensive
cancer center and committed to participation in this
project. The screening tool items used by Glare/Chow
[8] were translated in German language by two
German native speakers with high level of fluency in
English independently. The two versions were com-
pared and the final wording and examples were deter-
mined by the expert group. In order to avoid that all
patients admitted to the participating units had to be
fully screened, two filter questions were installed. Fol-
lowing the German “Evidenced-based Guideline: Pal-
liative care for patients with incurable cancer” stating
that “all patients must be offered palliative care fol-
lowing the diagnosis of incurable cancer, regardless of
whether cancer-specific therapy is being implemented”
screening should only be done for patients with
incurable cancer [12]. As second filter the surprise
question (with a cut off of 12 months life expectancy)
was used [13]. The proposed phenomenological
screening procedure contains the two filter questions
followed by a German version of Glare’s working
group tool [8, 14] with five domains including ten
items (see Table 1).
Study design and material
Ethical approval of the local ethics committee was
obtained before starting the study. According to the data
protection officer of the university hospital patient
consent was not necessary. Cooperating wards had given
written informed consent to the procedure of data col-
lection. Between January and August 2017 the screening
tool was applied in four cancer care settings of a univer-
sity hospital: respiratory medicine, haematology/oncol-
ogy, gynaecology and palliative medicine. All admissions
to these settings were first assessed by a study nurse at
the day of admission or the following working day if they
Table 1 Screening tool
Items Possible
points
Points
patient
Diagnosis: metastatic or locally advanced cancer 2
Functional status score: ECOGa 0–4
Fully active, able to carry on all pre-disease
performance without restriction
0
Restricted in physically strenuous activity but
ambulatory and able to carry out work
of a light or sedentary nature
1
Ambulatory and capable of all selfcare but
unable to carry out any work activities;
up and about more than 50% of waking hours
2
Capable of only limited selfcare; confined to bed
or chair more than 50% of waking hours
3
Completely disabled; cannot carry on any
selfcare; totally confined to bed or chair
4
one or more serious complications of advanced
cancer usually associated with a prognosis
of < 12 months (e.g. brain metastases,
hypercalcemia, delirium, spinal cord
compression, cachexia)
1
one or more serious comorbid diseases also
associated with poor prognosis
of < 12 months (e.g. moderate-severe COPD
or CHF, dementia, AIDS, end stage renal failure,
end stage liver cirrhosis)
1
Palliative care problems: 1 each
Symptoms uncontrolled by standard
approaches
Moderate to severe distress in patient
or family, related to diagnosis or therapy
(personal purposes/expectations, educative
or informational needs, cultural factors
affecting the treatment)
Patient/family concerns about course
of disease and decision making (including
realisation of power of attorney/patient
decree)
Patient/family requests palliative care
consultation team
Team needs assistance with complex decision
making or determining goals of care
(e.g. value/risks of treatment, desire to die)
Prolonged length of stay (> average length
of stay)
Total score 0–14
a ECOG Eastern Cooperative Oncology Group Performance Status
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met the inclusion criteria: i) aged ≥18 years, ii) treated in
case of a cancer disease, iii) not assessed within this
same trial during the last 3 months.
If evaluated positive for study inclusion, further assess-
ment was triggered and the study nurse provided the
ward with the necessary documents. One of the physi-
cians caring for the patient at the study site answered
the filter questions within three working days: i) incur-
able advanced cancer (yes/no), and ii) whether he/she
would be surprised if the patient died within 1 year (sur-
prise question) (yes/no).
In case the cancer disease was incurable (yes) and the
surprise question was answered with ‘no’, the physician
filled out the screening tool identifying SPC needs and
the Integrated Palliative Outcome Scale for professionals
(IPOS, staff version). IPOS is an instrument capturing
the most important concerns of patients in PC e.g.
symptom burden and psychosocial aspects. These as-
pects are rated from 0 (no effect) to 4 (overwhelmingly)
and summarized into a sum score in which higher scores
indicate lower outcomes [15]. For this study it was used
as an external criterion as there are currently no standard
measures that could be used to define the needs of SPC.
Subsamples at each site were employed to perform
inter-rater (by two different professionals at the same
assessment day) and test-retest (second rating by same
professional within three to five working days after initial
assessment) reliability for the screening tool. Subsample
size depended on the return rate and 54 pairs were
considered sufficient to significantly prove moderate
agreement [16]. For test-retest subsample the ‘Self-care
Index’ (Selbstpflegeindex, SPI) as an indicator of status
deterioration was captured. SPI is part of the German
routine assessment instrument “Outcome-oriented
Nursing Assessment” (‘ergebnisorientiertes Pflege As-
sessment©’, ePA©) and is meant to predict the risk of in-
sufficient care after discharge from hospital. The SPI
consists of ten items and its sum score ranges from 10
(= maximum impairment of self-care) and 40 (= full
ability of self-care) [17].
Additionally sociodemographic data such as age, gen-
der, performance status (Eastern Cooperative Oncology
Group (ECOG)) [10], primary diagnosis and connection
to SPC at home or during hospital stay as well as de-
cease during the survey period were collected. Previous
or existing contact to SPC was registered and is to be
regarded as an indication of existing SPC needs as those
are not easily to determine otherwise.
To be 95% confident that problems with a probability
of 10% will be detected [18] the target sample size for
validation was calculated with 30–40 for each setting
(∑90–120).
All physicians were instructed in using the screening
tool before data collection. In order to support the
implementation of such a screening tool, all recruiting
sites were supported during the assessment phase by
regular site visits and phone calls of the study nurse.
Each time the study nurse brought new screening tools
for admitted patients that fulfilled the inclusions criteria
she checked if the other tools were conducted in time
and reminded the physicians if necessary. Minimum fre-
quency of visits was two per week. With every patient
included in the study a contact on site to deliver the
study documents and one more to collect the results
took place.
Data analyses
The instrument was tested in terms of psychometric val-
idation with analysis of its validity and reliability in ac-
cordance with the recommendations of Streiner and
Norman [19] regarding the main components of health
measurement instrument validations. IBM SPSS Statis-
tics 21 (SPSS Inc., Chicago, IL, USA) [20] for Windows
was used for statistical analyses.
Results were considered significant if p < 0.05.
Validity
Content validity ensures that there are no important
aspects of the targeted outcome missed by the scales
[19]. In this study it arises out of the development of the
screening tool.
For construct validity convergent and discriminant val-
idity was evaluated. Convergent validity was checked by
using Pearson correlations between screening score and
sum score of IPOS as an external criterion based on the
hypothesis that an instrument measuring comparable as-
pects should show a substantial effect with correlation
values > 0.5 [21]. For discriminant validity, association
between the screening tool and different patient- and
disease-related aspects were examined with group
comparisons. This was done to evaluate if the screening
tool was sensitive to these patient- and disease-related
factors. Differences in sum score of the screening tool
between groups of patients with varying age (in groups),
gender and primary disease were investigated. T-tests
and one-way analysis of variance (ANOVA) were used.
Criterion validity was checked by using concurrent
and predictive validity. For concurrent validity we ana-
lyzed whether the patient was already in contact to PC
at home or during hospital stay as a criterion for group
comparison expecting that admissions with connection
to PC show higher screening scores. Predictive validity
was evaluated by group comparison between admissions
that deceased during the survey period and those who
didn’t, using the hypothesis that deceased admissions
present higher screening scores, due to a higher symp-
tom burden close to death [22].
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Reliability
For internal consistency Cronbach’s alpha and ‘alpha if
item deleted’ were calculated for single screening items.
Values between 0.7 and 0.9 were considered to indicate
good psychometric values [23].
For inter-rater and test-retest reliability Cohens Kappa
was used for single screening items. To guarantee a
stable condition for test-retest only patients were in-
cluded that showed differences in SPI ≤ 10% between
first to second estimation. Values between 0.4 and 0.75
indicate good agreement [24]. For screening score Pear-
son correlations were used with values higher than 0.5
indicating a substantial effect [21].
Determining a cut point for SPC needs
We analyzed positive predictive values (PPV) and nega-
tive predictive values (NPV) by defining patients as in
need of SPC by i) existing contact to PC unit, inpatient
or outpatient consultation team or ii) ≥ 1 item was
scored with 3 or 4, which is meant to require high
clinical attention in the IPOS assessment [25]. We used
a screening score ≥ 5 following Glare/Chow [8] and com-
pared the results to higher and lower scores.
Results
Recruitment and study population
Between January 9th and August 31st 2017 a total of
n = 2140 admissions at the 4 units were recorded.
Considering the inclusion criteria, n = 1070 patients were
excluded because of non-cancer-diseases and n = 2 be-
cause of organizational loss. Due to short-term hospital
discharge (n = 70), transfer to another ward (n = 19) or
rapid death (n = 8) n = 97 admissions dropped out. N =
234 admissions were excluded because they had already
been assessed within this same trial during the preceding
3 months. For n = 737 admissions the study assessment
was triggered and for n = 455 completed by the physician
within three working days after admission. Further n =
247 patients were excluded after the two initial ques-
tions, because their cancer disease was non-advanced or
curable (n = 155) or the surprise question was answered
with ‘yes’ (n = 92). Remaining N = 208 patients were in-
cluded for the validation process of the screening tool
(see Fig. 1). N = 9 of these were screened twice because
of multiple admissions with a greater interval than 3
months during the survey period. For n = 100 patients
an estimation of two different professionals at the day of
the initial assessment and for n = 76 patients an
test-retest estimation of the same professional was
performed.
The 208 patients were mainly female (54.8%) and
mean 63.47 years (SD ± 13.383, range 21–96 years). Their
performance status was mainly ECOG 2 (23.6%), ECOG
3 (19.7%) and ECOG 4 (20.7%) (see Table 2).
Screening score
The mean screening score was 7.15 (SD ± 2.597) with
scores ranging from 2 to 13 (see Figs. 2 and 3).
Psychometric properties
Validity
Content validity was ensured via a scoping review of the
literature on screening tools for SPC needs and the sys-
tematic collection of trigger points content validity.
Convergent validity was tested with Pearson correla-
tions between screening scores and IPOS sum score. To
calculate the IPOS sum score < 50% of missing items
were tolerated and imputed by a mean score based on
the items completed. In n = 57 cases (27.4%) more than
50% of the IPOS items were missing and no sum score
was calculated. The Pearson correlation coefficient
shows a two-sided significant (p < 0.01) and substantial
correlation effect (r = 0.547; n = 151).
For discriminant validity differences in screening score
in patient- and disease-related aspects were evaluated.
The physician’s estimation of the screening tool is inde-
pendent of patient’s age (in groups) (F(7, 200) = 1.654,
p = .122), gender (t206 = 1.615, p = .108) and primary
diagnosis (F(22, 185) = 1.405, p = .166) (see Table 2).
Criterion validity: For concurrent validity screening
scores of patients with connection to SPC by PC unit,
inpatient or outpatient PC consultation team (n = 93;
44.7%, mean screening score 9.27 ± 1.695) and without
connection to PC (n = 110; 52.9%, mean screening score
5.44 ± 1.845) were compared. N = 5 patients (2.4%) were
excluded, because information about connection to PC
at home were not available. Screening score is signifi-
cantly higher of admissions with connection to PC
(t201 = − 15.303, p < 0.01) (see Table 2). For predictive
validity screening scores of patients who deceased dur-
ing the survey period (n = 63, 30.3%, mean screening
score 8.59 ± 2.380) and those who didn’t (n = 145, 69.7%,
mean screening score 6.52 ± 2.441) were compared.
Screening score of deceased patients shows a significant
higher value (t206 = − 5.643, p < 0.01) (see Table 2).
Reliability
Internal consistency was calculated for the single items
of the screening tool. Cronbach’s alpha was α = .600 and
Cronbach’s alpha if item deleted ranged from .513 to
.607 for each single item. Deleting the item ‘diagnosis:
advanced or metastatic cancer’ would improve the in-
ternal consistency to .607.
Inter-rater reliability was tested for n = 100 patients.
Cohens Kappa ranged from κ = .220 (patients’/ families’ con-
cerns) to κ = .620 (patient/family asks for PC consultation).
Pearson’s correlation coefficient shows a two-sided signifi-
cant (p < 0.01) substantial effect (r= .745) (see Table 3).
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Test-retest reliability was performed for n = 76 pa-
tients. N = 10 patients were excluded due to a change of
SPI values of more than 10% (n = 7) or because the SPI
was not recorded (n = 3). Cohens Kappa ranged from
κ = .041 (team assistance needed) to κ = .570 (patient/
family request PC consultation) (see Table 3). Pearson’s
correlation coefficient shows a two-sided significant
(p < 0.01) substantial effect (r = .694).
Determining a cut point for SPC needs
A screening score ≥ 5 showed a PPV of 56.7% referring
to the need for SPC treatment evident due to a preexis-
tent contact to PC unit, inpatient or outpatient consult-
ation team. Hence, more than half of the patients with a
score ≥ 5 were already in contact with SPC, and a NPV
of 100%, implied that no patient would be missed.
Referring to IPOS estimations a screening score ≥ 5
had a PPV of 95.9% including that almost all patients
with a score ≥ 5 had one or more symptoms that
requires clinical attention. Nevertheless it had a NPV
of 37.0% meaning that almost two-third of patients
with ≥1 symptom that requires clinical attention
would be missed.
Analyzing PPV and NPV for a cut point ≥4 in com-
parison, lead to lower values in total. Using a cut point
≥6 shows higher PPVs, but lower NPVs (see Table 4).
Using a score ≥ 5, in 80.8% of the preselected patients
in our cohort and in 36.9% of the total cohort of patients
with malignant disease included after application of
exclusion criteria and drop-outs a contact to SPC would
have been triggered.
Discussion
This study is to the authors’ knowledge the first valid-
ation of a screening procedure in German language
identifying SPC needs of adult patients with advanced
cancer and the first using filter questions as a pre-
screening. We could show that an assessment of SPC
needs in cancer care settings is feasible and the
suggested tool presents a valid instrument for physicians
to initiate a PC consultation.
The screening score for SPC needs of all screened pa-
tients was rated high by the physicians and the majority
of patients were screened positively for SPC, probably
caused by the filter criteria that limited the study popu-
lation: a) an incurable and advanced cancer disease and
b) that the physician would not be surprised if the
Fig. 1 Recruitment. Legend: a Disabled access to patient file. b Haematology/Oncology n = 32; Gynaecology n = 112; Respiratory Medicine n =
113; Palliative Care n = 10
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admitted patient died within 1 year and by the fact that
part of the study population was recruited from the PC
ward. In particular the surprise question has been pro-
posed for screening; however recent evidence from sys-
tematic reviews shows heterogeneous results regarding
predictive value and accuracy. Downar et al. [26] found
that “the surprise question performs poorly to modestly
as a predictive tool for death”, however for cancer sig-
nificantly better than for non-cancer diagnosis. White et
al. [27] report a moderate accuracy, with a - compared
to other diseases - higher sensitivity (79%) for cancer pa-
tients. Our study may add to the claim to determine
whether the combination of the surprise question with
other clinical indicators may improve the identification
of patients with SPC needs. For clinical practice the use
of filter questions ahead of a dedicated screening may be
a feasible compromise between limited resources for
screening on the one hand and adequate case-finding on
the other hand. Additionally, it must be clear that with
any tool also unscreened or negatively screened patients
may develop needs, which should then lead to integra-
tion of specialized services.
Overall the screening tool showed satisfactory validity.
Missing data in the IPOS lead to an exclusion of almost
one third of the screened patients in analysis of conver-
gent validity. As the IPOS sum score was used as an
external criterion, we could only use those with less than
half of all data missing. Imputing data in questionnaires
Table 2 Patient demographic and disease-related data and association with screening score
N = 208 Mean score ± SD Test/Test statistic Significance
Gender male 45.2% 7.47 ± 2.413 t-Test: t206 = 1.615 p = .108
female 54.8% 6.89 ± 2.722 p = .122
Age Years;
mean 63,47 ± 13,383
range 21–96
21–30 7.50 ± 2.121 one-way ANOVA
(groups):
F(7, 200) = 1.65431–40 7.40 ± 1.776
41–50 8.47 ± 2.452
51–60 6.90 ± 2.564
61–70 6.91 ± 2.914
71–80 6.72 ± 2.447
81–90 8.25 ± 2.236
> 90 9.50 ± 0.707
Performance status ECOG 0 5.3% 3.09 ± 1.044 one-way ANOVA:
F(4, 203) = 120.081
p < 0.01
ECOG 1 30.8% 5.02 ± 1.386
ECOG 2 23.6% 6.78 ± 1.571
ECOG 3 19.7% 8.93 ± 1.233
ECOG 4 20.7% 10.09 ± 1.571
Primary diagnosis Bronchial carcinoma 16.3% 7.00 ± 2.807 one-way ANOVA:
F(22, 185) = 1.405
p = .166
Mammary carcinoma 14.4% 6.67 ± 2.758
Carcinoma of the female
genital tract
9.1% 5.79 ± 2.149
Renal cell carcinoma 5.3% 7.36 ± 3.042
Myelomatosis 4.8% 5.70 ± 2.163
Leukemia 4.8% 6.30 ± 1.947
Colon cancer 4.3% 8.33 ± 2.179
Lymphoma 4.3% 6.56 ± 2.242
Esophageal cancer 4.3% 8.11 ± 1.453
Pancreatic carcinoma 4.3% 7.67 ± 2.598
others 28.1% 7.97 ± 2.575
Connection to PC yes 44.7% 9.27 ± 1.695 t-Test: t201 = −15.303 p < 0.01
no 52.9% 5.44 ± 1.845
missing data 2.4%
Decease during survey yes 30.3% 8.59 ± 2.380 t-Test: t206 = −5.643 p < 0.01
no 69.7% 6.52 ± 2.441
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with more than half of all data missing was not consid-
ered adequate. The high percentage of missing values in
the IPOS might have been occurred due to the fact that
some of the IPOS items query symptoms and psycho-
social aspects, which may not be part of routine medical
history and assessment in oncological settings (e.g. if the
patient was in peace during the last 3 days). However,
two-third of the screened patients could be included in
the analysis, which showed a substantial correlation be-
tween the instruments as they both strive to measure
important aspects in SPC. Concerning patient- and
disease-related aspects the instrument is stable and inde-
pendent and does not show significant differences in
screening score between age, gender and primary diag-
nosis. While age and primary site showed no statistical
differences, this reflects the small sample sizes of the
subcategories. They show intuitive trends which would
be significant in a large enough study designed to test
these hypotheses. Effect of age is bimodal: Patients under
50 and over 80 have greater needs than those in the 50–
80 age groups. As expected, patients already in contact
to PC showed significantly higher screening scores than
those without contact (9.27 vs. 5.44). It is noteworthy
that almost half the patients screening positive were
already known to SPC, acknowledging individual PC
needs. This supports concurrent validity. In the study by
Glare et al. [28] it was found that about two thirds of all
admitted patients to a gastrointestinal oncology ward
did screen positive but very few of them were previously
known to the palliative care service. Furthermore pa-
tients that deceased during the study period had signifi-
cantly higher values than those who didn’t (8.59 vs.
6.52), like it was demonstrated in a previous study by
Glare/Chow [8] where the mean score was 5.0 when sur-
vival time was shorter than 6 months vs. a mean score of
3.3 when survival time was longer than 6months. The
Fig. 2 Screening score by patient
Fig. 3 Answers per item. Legend: a ECOG = Eastern Cooperative Oncology Group Performance Status
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overall higher sum scores in our study compared to
Glare/Chow [8] may be due to the fact the population
was preselected by the filter questions and about one
third of the study population was recruited from the
SPC ward.
Reliability of the screening tool showed moderate
values in internal consistency, maybe caused by the
heterogeneity and complexity of the evaluated
phenomenon [23]. Deleting one of the items with low
correlations would possibly lead to an impairment of
content validity [19]. For inter-rater as well as test-
retest reliability the instrument presents significantly
substantial correlations between the screening scores
of both estimations. Single items had a mostly good
agreement. Four single items (‘one or more severe
complications, often associated with a prognosis of <
12 months’; ‘patient/family concerns about course of
disease and decision making’; ‘team needs assistance
with complex decision making or determining goals
of care’ and ‘prolonged length of stay (> average
length of stay)’) showed poor agreement in inter-rater
and test-retest estimations. Different levels of experi-
ences of the physicians could constitute these differ-
ences as well as difficulties to rate these aspects in
general. In test-retest changes of the aspects between
first and second estimation are conceivable, which
however couldn’t be captured by analyzing the SPI
(e.g. if team needs support by PC consultation). Using
a cut point of ≥5 showed needs of SPC consultation
for 80.8% of the screened patients. Referring to all pa-
tients that were assessed this sums up to a proportion
of 36.9%, which is comparable to a recent study of
Glare/Chow using the same NCCN criteria (34% of
assessed patients in needs) [8].
Calculations of positive and negative predictive
values referred to the need for SPC treatment evident
due to a preexistent contact to PC unit, inpatient or
outpatient consultation team or IPOS estimations.
Both definitions of patients in need are deficiently.
Defining patients in need by judgment of a special-
ized palliative care professional (or patients own re-
port) could help to determine the cut point more
precisely.
Implementation of a screening tool for identifying
SPC needs as presented here could improve clinical
practice through timely and adequate SPC consult-
ation in all oncological settings. However, issues of
workload during daily routine for physicians have to
be taken into account. Therefore we recommend the
use of both filter questions to trigger the complete
screening procedure.
Study limitations
The study is based on four oncological settings within a
larger comprehensive cancer center at one German
university hospital. Therefore, the transferability of our
results to other settings may be somewhat hampered.
Table 3 Cohen’s Kappa and correlation coefficient of inter-rater and test-retest analysis on single item level
Factors Items Inter-Rater (n = 100) Test-Retest (n = 66)
κ p κ p
Diagnosis Diagnosis a a a a
ECOG ECOG .499 < 0.01 .535 < 0.01
Complications Complications .345 0.001 .318 0.007
Comorbidities Comorbidities .561 < 0.01 .402 0.001
Palliative relevant problems Symptoms .418 < 0.01 .545 < 0.01
Patient/family distress .540 < 0.01 .449 < 0.01
Patient/family concerns .220 .023 .262 0.030
Patient/family requests PC consult .620 < 0.01 .570 < 0.01
Team assistance needed .357 < 0.01 .041 0.735
Prolonged hospital stay .226 0.021 .168 0.138
r p r p
Screening Score .754 < 0.01 .703 < 0.01
a No calculation due to constant value
Table 4 Positive and negative predictive values (PPV and NPV)
for different cut points
Existing contact to PC IPOS≥ 1 item 3 or 4
PPV NPV PPV NPV
Cut point 4 49.2% 100% 91.0% 29.1%
Cut point 5 56.7% 100% 95.9% 37.0%
Cut point 6 63.4% 95.1% 96.1% 22.9%
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There will be needs in non-cancer patients as well, but
those were not investigated during this study.
Above that, the study had a large proportion of non-
responded and incomplete questionnaires (38.3%), although
a study nurse accompanied the screening process by regular
site visits and additional phone calls. This can be caused by
the perceived length of the questionnaires (screening tool
combined with IPOS), which may have be challenging to
assess during daily routine. The staff-version of the IPOS
was used for this study. We did not evaluate for how many
patients it would have been possible to complete the patient
version of the IPOS. Furthermore both questionnaires
(screening tool and IPOS) capture aspects that may not be
part of routine patient evaluation in oncological settings
and could cause discomfort for physicians. In addition
organizational challenges like short-term changes in attend-
ing physicians interfered with the recruitment process.
Therefore it is necessary to examine implementation strat-
egies, which assure minimal workload for screening in daily
routine. Besides using the filter questions a review whether
some of the screening items are already part of routine
documentation may be helpful.
We do not have information on the patients with SPC
needs we may have missed by the tool.
Furthermore we could only assign the deceased patient
to the deceased/survival dichotomy, when the patient
died during the study period and in the hospital setting.
Information about patients that died after the study or
in other settings was not yet available. That may have
had an impact on the group sizes and their screening
scores, respectively. This will be tested a planned follow-
up study after 1 year after recruitment ended.
Conclusions
This is the first validation of a phenomenological German
screening tool based on the NCCN Palliative Care guide-
lines. It can be concluded that the screening tool satisfactory
detects SPC needs of patients close to death that should
lead to a PC consultation. A more adequate and timely case
finding may be possible with our suggested combination of
two filter questions and a dedicated questionnaire.
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